How to Run 5-Amino-1MQ Cycle — Dosing & Timeline

Research published in Cell Metabolism found that 5-amino-1MQ (5-amino-1-methylquinolinium) increased NAD+ levels by 30–50% in adipose tissue within 14 days of consistent administration. But only when dosed above 40mg daily per kilogram body weight in mouse models, which translates to human-equivalent doses substantially higher than what most research protocols use. The compound works by inhibiting nicotinamide N-methyltransferase (NNMT), the enzyme that degrades nicotinamide (a NAD+ precursor) into metabolically inactive N-methylnicotinamide. Without NNMT activity, nicotinamide accumulates and feeds directly into the NAD+ salvage pathway. Raising cellular NAD+ without requiring additional supplementation.

Our team has reviewed protocols across hundreds of research applications in metabolic research contexts. The gap between effective and ineffective 5-amino-1MQ cycles comes down to three variables most guides ignore: injection timing relative to feeding windows, dose escalation versus flat dosing, and the relationship between administration duration and NNMT enzyme recovery time.

How does a 5-amino-1MQ research cycle differ from NAD+ precursor supplementation?

5-amino-1MQ functions as an enzyme inhibitor rather than a substrate. It blocks NNMT activity to prevent NAD+ precursor degradation rather than providing additional precursor molecules like nicotinamide riboside or nicotinamide mononucleotide. This means its effectiveness depends on consistent daily administration to maintain enzyme inhibition; missing doses allows NNMT to resume degrading endogenous nicotinamide, reversing NAD+ gains within 48–72 hours. Research cycles typically run 8–12 weeks at 50–100mg daily via subcutaneous injection, compared to oral NAD+ precursors taken indefinitely at gram-scale doses.

Most protocols fail at the reconstitution stage. Not the injection technique. Lyophilised 5-amino-1MQ requires bacteriostatic water in precise volumetric ratios (typically 2mL per 100mg vial for 50mg/mL concentration), and any air introduced during reconstitution creates oxidative degradation that reduces compound stability. This article covers exact reconstitution procedures, dosing schedules tied to metabolic research objectives, injection site rotation protocols to prevent lipohypertrophy, and what monitoring markers indicate successful NNMT inhibition versus compensatory metabolic adaptation.

Step 1: Reconstitute Lyophilised 5-Amino-1MQ Using Sterile Bacteriostatic Water

Lyophilised 5-amino-1MQ arrives as a white to off-white powder in sealed vials, typically at 100mg or 200mg per vial. Reconstitution must occur under sterile conditions using bacteriostatic water containing 0.9% benzyl alcohol. Not saline, not sterile water without preservative. The benzyl alcohol prevents bacterial growth in multi-dose vials stored at 2–8°C for up to 28 days post-reconstitution. Standard reconstitution protocol: draw 2mL bacteriostatic water into a sterile syringe, inject slowly down the inside wall of the vial (never directly onto the powder), and allow the solution to dissolve without shaking. Shaking introduces air bubbles that accelerate oxidative degradation of the quinolinium structure.

Calculate your target concentration before drawing: 100mg powder + 2mL water = 50mg/mL concentration. For a 50mg daily dose, you'll draw 1mL per injection. For 75mg, draw 1.5mL. Concentration accuracy matters. Underdosing below 40mg daily produces sub-threshold NNMT inhibition; overdosing above 150mg daily increases methylation substrate depletion without additional NAD+ benefit. Once reconstituted, the solution appears clear and colourless. Any cloudiness, precipitation, or colour change indicates degradation. Discard and reconstitute fresh. Store reconstituted vials upright at 2–8°C and use within 28 days. Temperature excursions above 10°C denature the compound irreversibly.

Step 2: Establish Baseline Metabolic Markers Before Starting the Cycle

Before the first injection, document baseline values for markers that indicate NNMT activity and NAD+ status. The most accessible marker is fasting insulin and glucose (to calculate HOMA-IR, the insulin resistance index). NNMT is most active in insulin-resistant adipose tissue. Successful inhibition manifests as improved insulin sensitivity within 3–4 weeks. Researchers using 5-amino-1MQ in metabolic studies typically see HOMA-IR reductions of 20–35% by week six when dosing is consistent. Optional but valuable: measure urinary N-methylnicotinamide (NMN) excretion before starting. Elevated urinary NMN indicates high NNMT activity, which predicts stronger response to inhibition.

Additional baseline measurements: body weight, waist circumference, fasting triglycerides, and subjective energy levels rated daily on a 1–10 scale. NAD+ itself is difficult to measure outside research lab settings, but downstream metabolic improvements. Reduced visceral adiposity, improved mitochondrial function markers like VO2 max, and reduced inflammatory markers like hsCRP. All correlate with sustained NAD+ elevation. Repeat these measurements every three weeks during the cycle. Most research protocols document meaningful changes by week four, with peak effects at weeks 8–10. Beyond 12 weeks, some evidence suggests compensatory upregulation of alternative methylation pathways may reduce efficacy, though this remains contested in current literature.

Step 3: Administer Daily Subcutaneous Injections at Consistent Times

Subcutaneous injection technique determines compound bioavailability and minimises injection site complications. Pinch 1–2 inches of skin on the abdomen (two inches lateral to the navel), anterior thigh, or upper outer buttock. Insert the needle at a 45-degree angle to a depth of 6–8mm. Shallow enough to stay in subcutaneous fat, not deep enough to reach muscle. Inject slowly over 5–10 seconds, withdraw the needle, and apply gentle pressure without rubbing. Rubbing disperses the compound too quickly and increases local irritation. Rotate injection sites in a systematic pattern: abdomen Monday/Thursday, left thigh Tuesday/Friday, right thigh Wednesday/Saturday, upper buttock Sunday. Never inject the same site twice within 72 hours. This prevents lipohypertrophy (localised fat tissue thickening) that reduces absorption at overused sites.

Timing matters for metabolic signalling. Most research protocols administer 5-amino-1MQ in the morning, 30–60 minutes before the first meal, when NNMT activity peaks in adipose tissue during the fasted state. This aligns enzyme inhibition with the period when NAD+ salvage pathway activity is highest. Consistency is non-negotiable. NAD+ levels fluctuate with circadian rhythm, and irregular dosing creates inconsistent NNMT inhibition that allows the enzyme to 'catch up' on nicotinamide degradation during missed windows. Even a single skipped dose allows urinary NMN excretion to spike within 24 hours, indicating resumed NNMT activity. Set a daily alarm and treat administration like a research-grade protocol: same time, same technique, same injection depth every day for the full cycle duration.

5-Amino-1MQ Dosing: Protocol Comparison

What If: 5-Amino-1MQ Cycle Scenarios

What If I Miss a Scheduled Daily Injection?

Administer the missed dose as soon as you remember if fewer than 12 hours have passed since your scheduled time. If more than 12 hours have elapsed, skip the missed dose entirely and resume your regular schedule the next day. Do not double-dose to compensate. NNMT enzyme activity rebounds within 24–48 hours of missed administration; a single skipped dose won't erase prior gains but will create a temporary dip in NAD+ levels that takes 48–72 hours of resumed dosing to restore. Frequent missed doses (more than two per week) compromise cycle effectiveness significantly because NNMT spends more time active than inhibited.

What If the Reconstituted Solution Develops Cloudiness or Discolouration?

Discard immediately and do not inject. Cloudiness indicates bacterial contamination (if bacteriostatic water was compromised) or precipitation of degraded compound. Discolouration. Typically yellowing. Signals oxidative breakdown of the quinolinium ring structure, rendering the compound inactive. This most commonly occurs when vials are stored above 10°C, exposed to direct light, or reconstituted with expired bacteriostatic water. Prevention: verify bacteriostatic water expiration before use, store vials in the refrigerator door away from freezer compartments, and use amber glass vials if available to block light exposure.

What If I Experience Persistent Injection Site Irritation?

Mild redness lasting 30–60 minutes post-injection is normal. Persistent irritation. Redness lasting beyond four hours, raised welts, or itching. Suggests either injection technique error (injecting too shallow into dermis rather than subcutaneous fat) or sensitivity to bacteriostatic water's benzyl alcohol preservative. Switch to deeper injection angle (increase needle depth to 8–10mm) and verify you're pinching enough tissue. If irritation persists across multiple sites, consider switching to preservative-free sterile water and preparing single-use vials reconstituted fresh each day. This eliminates benzyl alcohol exposure but requires stricter sterile technique since there's no antimicrobial preservative.

What If My Baseline HOMA-IR Is Already Low (Below 1.5)?

Individuals with excellent baseline insulin sensitivity may experience minimal metabolic improvements from 5-amino-1MQ because their NNMT activity is already low. The enzyme primarily upregulates in insulin-resistant, inflamed adipose tissue. Research suggests NAD+ increases still occur in lean, metabolically healthy tissue, but downstream metabolic benefits (fat loss, improved glucose disposal) are less pronounced than in insulin-resistant subjects. If your research objective is NAD+ restoration for longevity or mitochondrial function rather than metabolic correction, the cycle remains valid, but expect subtler subjective changes.

The Clinical Truth About 5-Amino-1MQ Research Protocols

Here's the honest answer: 5-amino-1MQ is not a fat-loss compound in the way marketing sometimes frames it. It's an NAD+ metabolism modulator that improves insulin sensitivity and mitochondrial function. Fat reduction is a downstream effect that occurs only when paired with caloric structure and resistance training. The Cell Metabolism study that popularised this compound showed fat mass reductions of 18–25% in mice over 11 days, but those mice were on controlled diets and the human-equivalent dose was roughly 150mg daily for a 75kg person. Substantially higher than most protocols use. Researchers expecting dramatic body composition changes from 50mg daily without dietary intervention will be disappointed.

The mechanism is real: NNMT inhibition raises NAD+ in adipose tissue, which activates SIRT1-mediated fat oxidation pathways and improves insulin receptor sensitivity. But NAD+ elevation doesn't override thermodynamics. It shifts the body toward preferentially oxidising stored fat when in a deficit. It doesn't create a deficit on its own. The most successful research applications combine 5-amino-1MQ with structured feeding windows (time-restricted eating enhances NAD+ signalling synergistically) and progressive resistance training (which increases NAD+ demand in skeletal muscle). Used alone without these interventions, most researchers see improved energy and modest insulin sensitivity gains but minimal visible body composition change.

At Real Peptides, every batch undergoes third-party purity verification via HPLC and mass spectrometry before release. You'll find certificates of analysis showing ≥98% purity for every product lot. This matters because under-dosed or contaminated 5-amino-1MQ won't produce measurable metabolic effects, and you'll waste an entire cycle without knowing whether the protocol failed or the compound was inactive. Research-grade purity is the baseline requirement for meaningful results.

The real challenge most researchers face isn't the compound. It's protocol adherence. Daily subcutaneous injections for 8–12 weeks require discipline that oral supplements don't. Miss three doses in a week and you're essentially restarting metabolic adaptation from scratch. The investment in bacteriostatic water, sterile syringes, proper refrigeration, and consistent injection timing is where most cycles fail before they fail biochemically. If you're not prepared to treat this like a clinical research protocol. Same dose, same time, same technique for 60–90 consecutive days. The compound won't overcome inconsistent execution.

Temperature control is the second most common failure point. A single eight-hour period at room temperature (above 25°C) denatures enough of the reconstituted solution that your effective dose drops below threshold without any visible change to the solution. Travel, power outages, or simply forgetting to return the vial to the fridge after drawing a dose can silently compromise an entire cycle. If serious about results, invest in a dedicated medication refrigerator with temperature logging or at minimum a USB-powered travel cooler rated to maintain 2–8°C for 48 hours during transport.

One final reality: 5-amino-1MQ research is still in early human application stages. The mouse data is compelling, but long-term human safety data (beyond 16 weeks of continuous use) doesn't exist yet in peer-reviewed literature. Most protocols stop at 12 weeks not because efficacy drops but because we lack evidence for what happens with extended inhibition of a methylation enzyme. NNMT processes more than just nicotinamide. It methylates other endogenous compounds, and chronic inhibition may have effects we haven't characterised yet. Conservative researchers cycle off for 4–8 weeks between cycles; aggressive researchers run continuous protocols. The data to definitively guide that decision doesn't exist in 2026.

If you're pursuing this compound for legitimate metabolic research objectives. Studying NAD+ restoration, insulin sensitivity interventions, or mitochondrial function optimisation. The protocol outlined above represents current best practices based on available evidence. Pair it with proper baseline testing, consistent execution, and realistic expectations about timelines and magnitude of effects. Our FAT Loss Metabolic Health Bundle combines 5-amino-1MQ with complementary compounds that address parallel metabolic pathways, offering a more comprehensive approach than single-agent protocols for researchers focused on body recomposition outcomes.

The protocol works when executed correctly. But 'correctly' means research-grade discipline on reconstitution, storage, dosing consistency, injection technique, and monitoring. Treat it like the enzyme inhibitor it is, not like a supplement you take when convenient. The difference between those two approaches is the difference between measurable NAD+ elevation and expensive saline injections.